Recently I’ve contributed a small part in Tatum Anderson’s April 2017 article Public-Private Coalition’s: High-Profile Delinkage Policy For Emerging Vaccines. You can read the full article by going to my articles section or go directly to the article by clicking this link.

I’m always happy to give my opinions in to the world of both technical and commercial expertise, ideas and experience covering product types such as vaccines, cell therapies, monoclonal antibodies, gene therapies and diagnostics. You can contact me through our contact page.

I’d love to hear your insights on both this article, but also on any of the blog topics.